OPEN ACCESS SCIENTIFIC REFERENCE & REVIEW DIGEST; RNA VACCINE TECHNOLOGY

OPEN ACCESS SCIENTIFIC REFERENCE & REVIEW DIGEST

The landscape of mRNA nanomedicine – Nature Medicine – Review – 10 November 2022
Unlocking the promise of mRNA therapeutics – Nature Biotechnology – Review – 3 November 2022
Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic – Nature Medicine – Article – 27 October 2022
mRNA printers kick-start personalized medicines for all – Nature Biotechnology – News – 09 August 2022
The clinical progress of mRNA vaccines and immunotherapies – Nature Biotechnology – Review – 09 May 2022
Recent advancements in lipid–mRNA nanoparticles as a treatment option for cancer immunotherapy – J. Pharmaceutical Investigation – Review – 26 March 2022
The current clinical landscape of personalized cancer vaccines – Cancer Treatment Review – Anti-tumour Treatment Review – March 24, 2022
Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics – Drug Metab Pharmacokinet – 05 Feb 2022
Vaccines 2020: The era of the digital vaccine is here – Science Translational Medicine – Viewpoint – 15 Dec 2021
Nucleic acid delivery for therapeutic applications – Advanced Drug Delivery Reviews – November 2021
The tangled history of mRNA vaccines – Nature News – Review – 22 October 2021
mRNA vaccines for infectious diseases: principles, delivery and clinical translation – Nature Reviews – Drug Discovery – 25 August 2021
Lipid nanoparticles for mRNA delivery – Nature – Review – 10 August 2021
Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement – ACS – Review – 21 June 2021
mRNA vaccines manufacturing: Challenges and bottlenecks – Vaccine – Review – 15 April 2021
Clinical and immunological effects of mRNA vaccines in malignant diseases – Molecular Cancer – Review – 15 March 2021
The promise of mRNA vaccines: a biotech and industrial perspective – Nature – Review – 04 February 2020
mRNA-based therapeutics — developing a new class of drugs – Nature Reviews – Drug Discovery –19 September 2014
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA – Nucleic Acids Research – 01 November 2011
A 2020 vision for vaccines against HIV, tuberculosis and malaria – Nature Perspectives – 25 May 2011
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA – Immunity – 01 August 2005

DOWNLOAD LINKS for OPEN ACCESS SCIENTIFIC REFERENCE & REVIEW DIGEST

Peter A. Jensen2023-01-14T18:58:25+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.